Emergency Contraception Options: Focus on Ulipristal Acetate
Author(s) -
Sharon Cameron
Publication year - 2012
Publication title -
clinical medicine insights women s health
Language(s) - English
Resource type - Journals
ISSN - 1179-562X
DOI - 10.4137/cmwh.s7642
Subject(s) - ulipristal acetate , emergency contraception , levonorgestrel , ovulation , medicine , gynecology , clinical research , obstetrics , research methodology , pharmacology , family planning , population , hormone , environmental health
Ulipristal acetate (UPA) is a progesterone receptor modulator that is available for emergency contraception (EC) and can be taken up to 120 hours after unprotected intercourse. A meta-analysis of clinical trials comparing UPA with levonorgestrel (LNG) for EC, demonstrated that UPA has higher efficacy than LNG. This higher efficacy is supported by biomedical studies that have demonstrated that UPA is a more potent inhibitor of ovulation, being able to delay ovulation in the immediate preovulatory period, when LNG is no longer effective. A recent study that explored risk factors for failure of EC, demonstrated that obese women were at increased risk of EC failure, with either UPA or LNG. However, failure was significantly less amongst women receiving UPA than those receiving LNG. There is growing evidence therefore, that UPA should be the preferred oral method of EC
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom